Latest News

In March and April just 97 cases of prostate cancer were diagnosed throughout Hartford Healthcare compared with 233 cases in 2019. The stark decline holds true for digestive cancers with a 42 percent decline in diagnoses and breast cancer with a 30 percent decline in diagnoses compared to the same period in 2019.

Yale Cancer Center (YCC) scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair.

Smilow Cancer Hospital Care Center at Torrington, in collaboration with Agriventures Agway of Litchfield, provided a donation of flower and vegetable seed packets to the physicians, nurses, and staff at Charlotte Hungerford Hospital in Torrington.

The drug Tagrisso could offer hope to patients battling a form of lung cancer that typically hits people with little or no history of smoking, a new trial finds.

Five Yale Cancer Center physicians have received awards from Conquer Cancer, the American Society of Cancer Oncology Foundation. The grants are given in conjunction with the virtual scientific program of the 2020 ASCO Annual Meeting.

Doctors are reporting success with newer drugs that control certain types of cancer better, reduce the risk it will come back and make treatment simpler and easier to bear.

Results of a clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.

According to findings of a national study, the addition of low-dose, whole-brain radiotherapy (LD-WBRT) combined with chemotherapy improved progression-free survival (PFS) in patients with primary central nervous system lymphoma (PCNSL). These results are to be presented May 30 at 11:00 a.m., during the virtual Scientific Program at the annual meeting of the American Society of Clinical Oncology (ASCO).

New findings led by Yale Cancer Center researchers show data sharing improved survival for patients with advanced gastric cancers. The data will be presented on May 30 at 11:00 a.m., during the virtual Scientific Program at the annual meeting of the American Society of Clinical Oncology (ASCO).